{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Germany Drug Manufacturers - Specialty & Generic news", "home_page_url": "https://sharemaestro.com/newsreel/de/healthcare/drug-manufacturers-specialty-generic/", "feed_url": "https://sharemaestro.com/newsreel/de/healthcare/drug-manufacturers-specialty-generic/feed.json", "description": "Latest Drug Manufacturers - Specialty & Generic company headlines from Germany, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:7a3ca7923616fe6725d707ca6208a1fb2f4a69afa38f5bf33c43bcdb42459ae8", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQUmQtaXY4VFNISWRsOE9wU1JEZlU3TUkzaF9WeHhLMzFfVkxlaS1kZnB3UG5yTWdjcndXQUJyX3B5TGwzWWlGTmNrWm5vbXRqLWtnR1BqT25XNjhxZXpsT2pnN0xTamR1b2lVWTNRZnBvcXI1blYxeFdOSm1vS2huUG5hUTN4cmJwQlNlaDdTMFh2UW9kZjA5S2FyX0NfaGlJd3o4Yi1LWHVZbnN6OW1nUURmUkwtSEl0WHJiMzRudw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQUmQtaXY4VFNISWRsOE9wU1JEZlU3TUkzaF9WeHhLMzFfVkxlaS1kZnB3UG5yTWdjcndXQUJyX3B5TGwzWWlGTmNrWm5vbXRqLWtnR1BqT25XNjhxZXpsT2pnN0xTamR1b2lVWTNRZnBvcXI1blYxeFdOSm1vS2huUG5hUTN4cmJwQlNlaDdTMFh2UW9kZjA5S2FyX0NfaGlJd3o4Yi1LWHVZbnN6OW1nUURmUkwtSEl0WHJiMzRudw?oc=5", "title": "Die Evotec-Aktie f\u00e4llt nach Halbjahreszahlen und gekappter EBITDA-Guidance", "content_text": "Die Evotec-Aktie f\u00e4llt nach Halbjahreszahlen und gekappter EBITDA-Guidance", "date_published": "2026-08-14T05:05:49+00:00", "authors": [{"name": "AD HOC NEWS"}], "tags": ["Market update", "EVT"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "EVT", "name": "Evotec SE", "sentiment_url": "https://sharemaestro.com/sentiment/29b04225-86fc-4492-9acb-4ad0a081d4c2/"}]}}, {"id": "source:f24688ac4b49aeeb0e4d88979e328a0a6e96e368502d0f733fb24b04fa9f7824", "url": "https://finance.yahoo.com/healthcare/articles/viatris-vtrs-selling-tyrvaya-could-230317847.html", "external_url": "https://finance.yahoo.com/healthcare/articles/viatris-vtrs-selling-tyrvaya-could-230317847.html", "title": "Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine?", "content_text": "According to reports, on August 6, Harrow, Inc. (NASDAQ:HROW) announced a definitive agreement to acquire global rights to Tyrvaya nasal spray from Viatris Inc. (NASDAQ:VTRS) for up to $100 million. Under the deal terms, Harrow will pay $30 million in cash at closing, funded via cash on hand, with up to $70 million in contingent sales milestone payments. Expected to close in the second half of 2026, the transaction transfers a dry eye disease treatment approved in the U.S., China, and Taiwan to a specialized ophthalmic player, allowing Viatris to streamline its portfolio.Could Danaher Corporat", "date_published": "2026-08-13T23:03:17+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "VIA"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VIA", "name": "Viatris Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/e92f8bbe-0245-4de1-a36d-1a4306c6b65e/"}]}}, {"id": "source:75945c1d5efeb098163b135d5abb4ce99219477d7736af6fc2e6f09753d896bb", "url": "https://finance.yahoo.com/healthcare/articles/zoetis-receives-emergency-authorization-simparica-195100958.html", "external_url": "https://finance.yahoo.com/healthcare/articles/zoetis-receives-emergency-authorization-simparica-195100958.html", "title": "Zoetis Receives Emergency Use Authorization for Simparica Trio\u00ae (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies", "content_text": "Expands the solutions available to veterinarians to help address New World screwworm and gives added confidence for pet owners whose dogs and puppies are already receiving Simparica Trio Milestone demonstrates Zoetis' coordinated multi-species response to address New World screwworm across both companion animals and livestock PARSIPPANY, N.J., August 13, 2026--(BUSINESS WIRE)--Zoetis Inc. today announced that Simparica Trio has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of infestations caused by New World screwworm (Cochliomyia", "date_published": "2026-08-13T19:51:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "ZOE"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ZOE", "name": "Zoetis Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/9868334b-e8e6-4920-88df-16cb72348fce/"}]}}, {"id": "source:089743f13550a0eb23280103b41e8105a37f127064163297e8ab53eb57fa0359", "url": "https://finance.yahoo.com/technology/ai/articles/michael-burry-sends-fresh-ai-184329662.html", "external_url": "https://finance.yahoo.com/technology/ai/articles/michael-burry-sends-fresh-ai-184329662.html", "title": "Michael Burry Sends Fresh AI Warning on Nebius, Micron and Oracle", "content_text": "This article first appeared on GuruFocus. Michael Burry (Trades, Portfolio) has increased bearish positions tied to artificial intelligence and semiconductor stocks, while adding to selected long holdings, according to a Wednesday Substack post. Warning! GuruFocus has detected 3 Warning Signs with MU. Is MU fairly valued? Test your thesis with our free DCF calculator. Burry added to his short positions in Nebius Group (NASDAQ:NBIS), Micron Technology (NASDAQ:MU), Oracle (NYSE:ORCL) and the iShares Semiconductor ETF (NASDAQ:SOXX). The investor said he added to his NBIS position at $247, MU at $", "date_published": "2026-08-13T18:43:29+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ZOE"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ZOE", "name": "Zoetis Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/9868334b-e8e6-4920-88df-16cb72348fce/"}]}}, {"id": "source:f687ca88d44b8346269757b2f5464410caf7e9eea843f7769ef30c66c174f505", "url": "https://www.nasdaq.com/articles/viatris-vtrs-q2-2026-earnings-call-transcript", "external_url": "https://www.nasdaq.com/articles/viatris-vtrs-q2-2026-earnings-call-transcript", "title": "Viatris (VTRS) Q2 2026 Earnings Call Transcript", "content_text": "Image source: The Motley Fool. DATE Thursday, August 6, 2026 at 8:30 a.m. ET CALL PARTICIPANTS CEO - Scott SmithInterim CFO - Paul CampbellChief R&D Officer - Philippe MartinChief Commercial Officer - Corinne Le GoffHead of Capital Markets - Bill Szablewski TAKEAWAYS Revenue -- $3.8 billion, representing 3.5% operational growth year over year driven by strength in Greater China and complex generics in North America.Adjusted EBITDA -- $1.2 billion, reflecting an 8% operational increase versus the prior year due to operating leverage and cost discipline.Adjusted EPS -- $0.69, a 9% operational in", "date_published": "2026-08-13T18:13:22+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Earnings", "VIA"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VIA", "name": "Viatris Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/e92f8bbe-0245-4de1-a36d-1a4306c6b65e/"}]}}, {"id": "source:356b9804c9a950cf8dc50d3ef8ffae3b5a2bb261fcdebe7b7d66a4ec0cf11c6d", "url": "https://www.nasdaq.com/articles/zoetis-zts-q2-2026-earnings-call-transcript", "external_url": "https://www.nasdaq.com/articles/zoetis-zts-q2-2026-earnings-call-transcript", "title": "Zoetis (ZTS) Q2 2026 Earnings Call Transcript", "content_text": "Image source: The Motley Fool. DATE Thursday, Aug. 13, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Steve FrankChief Executive Officer - Kristin PeckChief Financial Officer - Wetteny Joseph TAKEAWAYS Revenue -- $2.5 billion, representing a flat result on a reported basis and a 1% decline on an organic operational basis driven by a 1% decrease in volume.Adjusted Net Income -- $781 million, declining 2% on an organic operational basis.Adjusted Diluted EPS -- $1.87, representing 4% growth year over year and benefiting from a lower share count.U.S. Segment Revenue ", "date_published": "2026-08-13T12:01:05+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Earnings", "ZOE"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ZOE", "name": "Zoetis Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/9868334b-e8e6-4920-88df-16cb72348fce/"}]}}, {"id": "source:0a85a48b2cacf1b114d9a9e35398c1241f3550813279879ac48b6d889d0ecdcc", "url": "https://seekingalpha.com/news/4632100-burry-adds-to-ai-shorts-says-nebius-is-what-the-top-of-a-boom-looks-like?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4632100-burry-adds-to-ai-shorts-says-nebius-is-what-the-top-of-a-boom-looks-like?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Burry adds to AI shorts, says \u2018Nebius is what the top of a boom looks like\u2019", "content_text": "Astrid Stawiarz Michael Burry disclosed updated stock positions on Wednesday, adding to his short bets on Nebius (NBIS [https://seekingalpha.com/symbol/NBIS]), Micron (MU [https://seekingalpha.com/symbol/MU]), Oracle (ORCL [https://seekingalpha.com/symbol/ORCL]), and the iShares Semiconductor ETF (SOXX [https://seekingalpha.com/symbol/SOXX]), while increasing his long positions in Mercado Libre (MELI [https://seekingalpha.com/symbol/MELI]) and Zoetis (ZTS [https://seekingalpha.com/symbol/ZTS]). Burry, the investor featured in \u201cThe Big Short,\u201d said in a Substack post [https://michaeljburry.subs", "date_published": "2026-08-13T07:51:41+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Earnings", "ZOE"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ZOE", "name": "Zoetis Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/9868334b-e8e6-4920-88df-16cb72348fce/"}]}}, {"id": "source:f75ea16844189b421b9414d161d65dac00511f68b592aae9a86aacc60294eb7e", "url": "https://finance.yahoo.com/markets/stocks/articles/amrx-stock-buy-growth-improves-155100927.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/amrx-stock-buy-growth-improves-155100927.html", "title": "Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?", "content_text": "Amneal Pharmaceuticals AMRX enters the second half of 2026 with higher guidance and a broader product pipeline. The company is expanding complex generics, biosimilars and specialty medicines while adjusted earnings and EBITDA improve. The trade-off is clear. Rytary has lost exclusivity, generic pricing remains competitive and complex launches carry regulatory and adoption risk. Valuation also sends a mixed signal, making execution central to the buy case. AMRX's 2026 Outlook Keeps Moving Higher Amneal raised 2026 net revenue guidance to $3.10-$3.20 billion from $3.05-$3.15 billion. Adjusted EB", "date_published": "2026-08-12T15:51:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "VIA"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "VIA", "name": "Viatris Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/e92f8bbe-0245-4de1-a36d-1a4306c6b65e/"}]}}, {"id": "source:c4fd0e3cf9945a691a10d4b7b0da152823529c1f8cc61148f28859a0fac2433b", "url": "https://finance.yahoo.com/healthcare/articles/remepy-raises-36-million-series-123000668.html", "external_url": "https://finance.yahoo.com/healthcare/articles/remepy-raises-36-million-series-123000668.html", "title": "Remepy Raises $36 Million Series A to Expand Its Hybrid Drug\u2122 Pipeline Through Pharmaceutical Partnerships and Advance Phase III of Hybridopa\u2122 for Parkinson's Disease", "content_text": "Funding brings total capital raised to $62 million as the Company expands pharmaceutical co-development partnerships and accelerates the Hybrid Drug category NEW YORK, Aug. 12, 2026 /PRNewswire/ -- Remepy, the pioneer of Hybrid Drugs, today announced the closing of a $36 million Series A financing round led by O.G. Venture Partners and M Ventures, the corporate strategic venture arm of Merck KGaA, Darmstadt, Germany, with participation of existing and new investors including NFX, Vine Ventures, Qumra Capital, TechAviv, 97212 Ventures, Fresh Fund, PsyMed Ventures, Tadmor Group, Key1 Capital, an", "date_published": "2026-08-12T12:30:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "MRK"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MRK", "name": "Merck KGaA", "sentiment_url": "https://sharemaestro.com/sentiment/d40575c6-c1e0-4c88-afb7-fa233fffc9b7/"}]}}, {"id": "source:4f8597c4c8a062ce80d677b79a8a5b8c7ebb5ac203f8b7f70566a5287a7e0563", "url": "https://finance.yahoo.com/markets/stocks/articles/haleon-plc-cash-tender-offer-124800075.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/haleon-plc-cash-tender-offer-124800075.html", "title": "Haleon plc: Cash tender offer for outstanding 2027 3.375% Fixed Rate Notes", "content_text": "LONDON, Aug. 11, 2026 /PRNewswire/ -- Haleon plc (the \"Company\" or \"Haleon\") (LSE/NYSE: HLN) today announces that its wholly owned subsidiary, Haleon US Capital LLC (the \"Offeror\") is offering to buy back any and all of its outstanding $1,999,350,000 3.375% Fixed Rate Senior Notes due March 2027. Bondholders will receive a price equal to the Total Consideration based on the Reference Yield and the Fixed Spread plus Accrued Interest (each as defined below) (the \"Tender Offer\"). This Tender Offer is in line with Haleon's previously stated capital allocation priorities. Together, with the planned", "date_published": "2026-08-11T12:48:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Balance sheet", "H6D0"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "H6D0", "name": "Haleon plc", "sentiment_url": "https://sharemaestro.com/sentiment/537ee44a-762e-4959-8cdd-22824afadba8/"}]}}, {"id": "source:ff0de28a8eb1eb4257d0a40950f5bc2fbef187fe2ef6ccd7d21eb947a77d693a", "url": "https://finance.yahoo.com/healthcare/articles/vtrs-q2-deep-dive-china-085322435.html", "external_url": "https://finance.yahoo.com/healthcare/articles/vtrs-q2-deep-dive-china-085322435.html", "title": "VTRS Q2 Deep Dive: China Growth, Pipeline Progress, and Margin Concerns Shape Outlook", "content_text": "VTRS Q2 Deep Dive: China Growth, Pipeline Progress, and Margin Concerns Shape Outlook Medication company Viatris (NASDAQ:VTRS) announced better-than-expected revenue in Q2 CY2026, with sales up 4.9% year on year to $3.76 billion. The company expects the full year's revenue to be around $14.75 billion, close to analysts' estimates. Its non-GAAP profit of $0.69 per share was 15% above analysts' consensus estimates. Is now the time to buy VTRS? Find out in our full research report (it's free). Viatris (VTRS) Q2 CY2026 Highlights: Revenue: $3.76 billion vs analyst estimates of $3.68 billion (4.9% ", "date_published": "2026-08-11T08:53:22+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "VIA"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VIA", "name": "Viatris Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/e92f8bbe-0245-4de1-a36d-1a4306c6b65e/"}]}}, {"id": "source:967d66c6b6a441fdd30771e77ba245554659d4b4e9f89a19e7e25f923ba0449e", "url": "https://news.google.com/rss/articles/CBMifEFVX3lxTFBuZW5ORnZJdmJsSHprbXhXSC1TUE1rX1V0MzM5SnZWVXZkRHdGTEZUaExtTGZuM2VtZzhtS1FJQ1U2XzRqT18wUFlEV0prT0xTZDRCb2doa281S0hSd0ZsUlQ3akwyMHdadUxYZUFxS0lEWXQ5a3lEN2VzZVrSAYIBQVVfeXFMT25EUGM3TFNhVXhNUUprSldmb1hwQkpDMlFXelNUWVV2SkZWVEJXTmxaeHQ2eURBS1VpNEU2R1paa3RjZ1hnaFRmaDZVRlhxZV9acndQbE1jVWNjcjRtUFg5ajkwOEs3WkwzWUFPeVlnRmdQWUs1bTFGa3NwOFMyUGg2dw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMifEFVX3lxTFBuZW5ORnZJdmJsSHprbXhXSC1TUE1rX1V0MzM5SnZWVXZkRHdGTEZUaExtTGZuM2VtZzhtS1FJQ1U2XzRqT18wUFlEV0prT0xTZDRCb2doa281S0hSd0ZsUlQ3akwyMHdadUxYZUFxS0lEWXQ5a3lEN2VzZVrSAYIBQVVfeXFMT25EUGM3TFNhVXhNUUprSldmb1hwQkpDMlFXelNUWVV2SkZWVEJXTmxaeHQ2eURBS1VpNEU2R1paa3RjZ1hnaFRmaDZVRlhxZV9acndQbE1jVWNjcjRtUFg5ajkwOEs3WkwzWUFPeVlnRmdQWUs1bTFGa3NwOFMyUGg2dw?oc=5", "title": "Dermapharm: EBITDA steigt, Prognose f\u00fcr 2026 best\u00e4tigt", "content_text": "Dermapharm: EBITDA steigt, Prognose f\u00fcr 2026 best\u00e4tigt", "date_published": "2026-08-11T08:21:38+00:00", "authors": [{"name": "4investors.de"}], "tags": ["Market update", "DMP"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "DMP", "name": "Dermapharm Holding SE", "sentiment_url": "https://sharemaestro.com/sentiment/69aa276b-d53f-4877-82f6-2d5c0a5602d6/"}]}}, {"id": "source:a23d7187c41094ebe485bf28371a06b528c06e8cb7dd60726ff1b14122a96952", "url": "https://finance.yahoo.com/healthcare/articles/haleon-singapores-agency-science-technology-034100676.html", "external_url": "https://finance.yahoo.com/healthcare/articles/haleon-singapores-agency-science-technology-034100676.html", "title": "Haleon and Singapore's Agency for Science, Technology and Research (A*STAR) Launch New Clinical Study on Women's Metabolic Health in Asia", "content_text": "A new clinical study on the multivitamin and mineral supplement Centrum is designed to generate evidence on metabolic health in midlife Asian women - a group often underrepresented in global nutrition research. The study will contribute to a better understanding of preventive healthcare and healthy ageing in Asian populations. SINGAPORE, Aug. 11, 2026 /PRNewswire/ -- Haleon, a leading consumer health company focused on better everyday health, and the A*STAR Institute for Human Development and Potential (A*STAR IHDP) today announced the launch of a new clinical study known as the Impact of Mult", "date_published": "2026-08-11T03:41:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "H6D0"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "H6D0", "name": "Haleon plc", "sentiment_url": "https://sharemaestro.com/sentiment/537ee44a-762e-4959-8cdd-22824afadba8/"}]}}, {"id": "source:5620b6753c39f463c1c413543a97cf2708a2e054abdc497bfcf7a789a950b4e6", "url": "https://finance.yahoo.com/healthcare/articles/odyssey-therapeutics-odtx-looks-fully-001932545.html", "external_url": "https://finance.yahoo.com/healthcare/articles/odyssey-therapeutics-odtx-looks-fully-001932545.html", "title": "Odyssey Therapeutics (ODTX) Looks Fully Valued As Earnings And Evotec Deal Refocus Attention", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Why Odyssey Therapeutics Stock Is Back In Focus Odyssey Therapeutics (ODTX) is drawing attention after reporting second quarter 2026 results that showed a larger net loss alongside a sharp change in reported loss per share from continuing operations. For the quarter ended June 30, 2026, Odyssey Therapeutics reported a net loss of US$52.79 million compared with US$41.24 million a year earlier. Basic and diluted loss per share from continuing operations was US$1.74, while the p", "date_published": "2026-08-11T00:19:32+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "EVT"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "EVT", "name": "Evotec SE", "sentiment_url": "https://sharemaestro.com/sentiment/29b04225-86fc-4492-9acb-4ad0a081d4c2/"}]}}, {"id": "source:3140ec8cc640c38ca24b29fc29c971c9deac3e750d58aafa7b3fa671440f283c", "url": "https://finance.yahoo.com/healthcare/articles/zoetis-zts-looked-winner-went-130909398.html", "external_url": "https://finance.yahoo.com/healthcare/articles/zoetis-zts-looked-winner-went-130909398.html", "title": "Zoetis (ZTS) Looked Like a Winner. What Went Wrong?", "content_text": "Brown Advisory, an investment management company, released its \"Brown Advisory Global Leaders Strategy\" for the second quarter of 2026 investor letter. A copy of the letter can be downloaded here. Brown Advisory's Global Leaders Strategy delivered a net return of 4.6% in the second quarter of 2026, underperforming its benchmark, the MSCI ACWI Net Index, which returned 14.9%. The relative weakness was driven mainly by underexposure to semiconductors and technology hardware, while software, cloud services, and financial holdings also weighed on performance. The strategy benefited from holdings i", "date_published": "2026-08-10T13:09:09+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ZOE"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ZOE", "name": "Zoetis Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/9868334b-e8e6-4920-88df-16cb72348fce/"}]}}, {"id": "source:599ac6a1a8cd9b5fbe0d00172f3ecc743e84a325b57094d53a96c1486a7dfa85", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.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?oc=5", "title": "Warum Viatris (VTRS) nach der Anhebung der Prognose und dem Abschluss eines Aktienr\u00fcckkaufs im Wert von 1,15 Milliarden US-Dollar um 6,4 % nachgibt", "content_text": "Warum Viatris (VTRS) nach der Anhebung der Prognose und dem Abschluss eines Aktienr\u00fcckkaufs im Wert von 1,15 Milliarden US-Dollar um 6,4 % nachgibt", "date_published": "2026-08-10T08:37:10+00:00", "authors": [{"name": "simplywall.st"}], "tags": ["Market update", "VIA"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VIA", "name": "Viatris Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/e92f8bbe-0245-4de1-a36d-1a4306c6b65e/"}]}}, {"id": "source:a3ee338d45a7934d90f10d063276d4da13a483e9f6f07ba3cb2eb0d374389b7f", "url": "https://finance.yahoo.com/markets/stocks/articles/us-stock-market-today-p-081128237.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/us-stock-market-today-p-081128237.html", "title": "US Stock Market Today: S&P 500 Futures Climb On Softer Jobs Data And Yields", "content_text": "Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. The Morning Bull - US Market Morning Update Monday, Aug, 10 2026 US stock futures are pointing higher this morning, with the S&P 500 contracts up around 0.6%, as investors weigh softer US jobs data against falling bond yields and cooler inflation expectations. July nonfarm payrolls showed a small job loss of 23,000 and weaker wage growth, which signals a slowing job market and less pressure from pay rises. At the same time, the 10 year Treasury yield has d", "date_published": "2026-08-10T08:11:28+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ZOE"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ZOE", "name": "Zoetis Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/9868334b-e8e6-4920-88df-16cb72348fce/"}]}}, {"id": "source:a5b082ee21530caa0ec5a13ac1d1081707b0bf2bdc113f3cdb9cce2541e4d6d6", "url": "https://finance.yahoo.com/markets/stocks/articles/zts-q2-deep-dive-leadership-032522195.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/zts-q2-deep-dive-leadership-032522195.html", "title": "ZTS Q2 Deep Dive: Leadership Shifts and Competitive Pressures Shape Guidance", "content_text": "ZTS Q2 Deep Dive: Leadership Shifts and Competitive Pressures Shape Guidance Animal health company Zoetis (NYSE:ZTS) fell short of the market's revenue expectations in Q2 CY2026, with sales flat year on year at $2.47 billion. The company's full-year revenue guidance of $9.22 billion at the midpoint came in 5.4% below analysts' estimates. Its non-GAAP profit of $1.87 per share was 1% above analysts' consensus estimates. Is now the time to buy ZTS? Find out in our full research report (it's free). Zoetis (ZTS) Q2 CY2026 Highlights: Revenue: $2.47 billion vs analyst estimates of $2.50 billion (fl", "date_published": "2026-08-10T03:25:22+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ZOE"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ZOE", "name": "Zoetis Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/9868334b-e8e6-4920-88df-16cb72348fce/"}]}}, {"id": "source:69cb2aa016c1707f11b0c766401a71243363639d769c28c5d2a05f5fdec01788", "url": "https://finance.yahoo.com/markets/stocks/articles/viatris-vtrs-down-6-4-011421686.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/viatris-vtrs-down-6-4-011421686.html", "title": "Viatris (VTRS) Is Down 6.4% After Raising 2026 Guidance And Completing Major Buyback Program", "content_text": "In early August 2026, Viatris Inc. reported higher second-quarter and year-to-date revenues, a six-month return to net profitability, raised its 2026 earnings guidance midpoint to US$14.75 billion, completed a US$1.15 billion share repurchase program covering 8.7% of shares, and affirmed a US$0.12 quarterly dividend. An interesting angle is that Viatris paired improved earnings and guidance with both capital returns and the FDA approval of its low-estrogen Gwyn Lo contraceptive patch, signaling concurrent investment in growth and shareholder distributions. We'll now examine how the raised 2026", "date_published": "2026-08-10T01:14:21+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Capital return", "VIA"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VIA", "name": "Viatris Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/e92f8bbe-0245-4de1-a36d-1a4306c6b65e/"}]}}, {"id": "source:3e3a1cf7dafc82bd1eb9734122831ac3b55fb655ff2742c22e2187ec9dbec24f", "url": "https://finance.yahoo.com/markets/stocks/articles/viatris-vtrs-stock-may-below-201039877.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/viatris-vtrs-stock-may-below-201039877.html", "title": "Viatris (VTRS) Stock May Be Below Fair Value Despite FDA Patch Approval", "content_text": "Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Viatris stock has delivered a strong 76.1% return over the past year, and the broader valuation checks still indicate the shares may be pricing in less than the company's fundamentals could justify. Viatris is up 76.1% over the last 12 months, which puts more focus on whether the recent share price better reflects the company's long term earnings power. Recent product news, including the FDA approval of the Gwyn Lo contraceptive patch and the agreement to ", "date_published": "2026-08-09T20:10:39+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "VIA"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VIA", "name": "Viatris Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/e92f8bbe-0245-4de1-a36d-1a4306c6b65e/"}]}}, {"id": "source:b79dfef99e14f83e6e7485a496aba4a45ab4c2e909ab425d2433d0cf424e054a", "url": "https://finance.yahoo.com/healthcare/articles/zoetis-q2-earnings-call-highlights-180354196.html", "external_url": "https://finance.yahoo.com/healthcare/articles/zoetis-q2-earnings-call-highlights-180354196.html", "title": "Zoetis Q2 Earnings Call Highlights", "content_text": "Key Points Interested in Zoetis Inc.? Here are five stocks we like better. Zoetis reported mixed second-quarter results: Revenue was $2.5 billion, flat reported and down 1% organically, while adjusted EPS rose 4% to $1.87 due partly to share repurchases. Weak U.S. companion-animal demand offset growth in livestock, diagnostics and international markets. Pet-care pressures led to a lowered outlook. Declining veterinary visits, selective pet-owner spending and increased competition hurt companion-animal and dermatology sales; Zoetis now expects full-year organic operational revenue to decline 3%", "date_published": "2026-08-09T18:03:54+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ZOE"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ZOE", "name": "Zoetis Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/9868334b-e8e6-4920-88df-16cb72348fce/"}]}}, {"id": "source:d7c85ea9f98992fedd11ce7513e654843bf7978254b4ba6e7cc6628a9a37fcb2", "url": "https://finance.yahoo.com/markets/stocks/articles/viatris-vtrs-raises-2026-guidance-141018376.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/viatris-vtrs-raises-2026-guidance-141018376.html", "title": "Viatris (VTRS) Raises 2026 Guidance, Is The 11% Gap Below Fair Value Enough?", "content_text": "Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Viatris raises 2026 guidance alongside completed buyback and fresh product approval Viatris (VTRS) has given investors a busy early August, pairing raised 2026 revenue guidance and completion of a multi year share repurchase program with new product news and an affirmed quarterly dividend. See our latest analysis for Viatris. The recent guidance lift, completion of a US$1.15b buyback and fresh product approval come after a strong run for Viatris, with a year to date share price re", "date_published": "2026-08-09T14:10:18+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Capital return", "VIA"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VIA", "name": "Viatris Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/e92f8bbe-0245-4de1-a36d-1a4306c6b65e/"}]}}, {"id": "source:d57b5b18af87a6c4c97d2c4c28d98cf6f03ef2e7928b939a0fe59ecb5ec288c0", "url": "https://seekingalpha.com/news/4629554-notable-healthcare-headlines-for-the-week-eli-lilly-novo-nordisk-and-pfizer-in-focus?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4629554-notable-healthcare-headlines-for-the-week-eli-lilly-novo-nordisk-and-pfizer-in-focus?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Notable healthcare headlines for the week: Eli Lilly, Novo Nordisk, and Pfizer in focus", "content_text": "Wall Street\u2019s major market averages ended higher on Friday after July's nonfarm payrolls surprised to the downside, showing an unexpected contraction in employment. The blue-chip Dow edged up 0.3%, the benchmark S&P 500 gained 0.62%, and the tech-focused Nasdaq Composite jumped 1.3%. The S&P 500 Health Care Index Sector (XLV [https://seekingalpha.com/symbol/XLV]) gained 1.92% during the week. The top S&P 500 healthcare gainers and losers for the last week are as follows: TOP GAINERS: Charles River Laboratories International (CRL [https://seekingalpha.com/symbol/CRL]) +15.04% Veeva Systems (VEE", "date_published": "2026-08-09T13:05:04+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Earnings", "ZOE", "VIA"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ZOE", "name": "Zoetis Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/9868334b-e8e6-4920-88df-16cb72348fce/"}, {"symbol": "VIA", "name": "Viatris Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/e92f8bbe-0245-4de1-a36d-1a4306c6b65e/"}]}}, {"id": "source:161ae05315211b77b7d05f75656d709c3eb9919aaa29e52f01198df72b131579", "url": "https://finance.yahoo.com/markets/stocks/articles/viatris-vtrs-stock-sees-modest-091144212.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/viatris-vtrs-stock-sees-modest-091144212.html", "title": "Viatris (VTRS) Stock Sees Modest Fair Value Lift After Q1 Results And Pipeline Progress", "content_text": "Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. The latest research on Viatris centers on a revised price target of US$22 per share and what that figure implies for investors following the story. Analysts are split, with more optimistic views pointing to execution on the product pipeline and cautious views questioning how fully the current stock price already reflects those expectations. As the article continues, you will see how this updated target fits into the evolving narrative around Viatris and ", "date_published": "2026-08-09T09:11:44+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "VIA"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VIA", "name": "Viatris Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/e92f8bbe-0245-4de1-a36d-1a4306c6b65e/"}]}}, {"id": "source:0e2193d480b51858bae723da5e9be28110a742428671295c878f83f7e95e3e4b", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPcFFSRlBiY2FJdzRMbXdSZ2R1cjJ2Q2NJWjlnX1BDdTJrWGgyZmRsRXBqMlprX0IzdnVsQ0lvNmFKejF2blNmbG1qTG9yTFhoVHFoQUg3YXFLdFFVX1I3dkQ0UkdvdGxReDRtUmMxLWtLLXZNbGJzSlVHTzhRVUhOOUxuSlozWmdRODlNMXpkOWtwNWU3Zk15bTg0LWExUDNIZ1ZNbV9Saw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPcFFSRlBiY2FJdzRMbXdSZ2R1cjJ2Q2NJWjlnX1BDdTJrWGgyZmRsRXBqMlprX0IzdnVsQ0lvNmFKejF2blNmbG1qTG9yTFhoVHFoQUg3YXFLdFFVX1I3dkQ0UkdvdGxReDRtUmMxLWtLLXZNbGJzSlVHTzhRVUhOOUxuSlozWmdRODlNMXpkOWtwNWU3Zk15bTg0LWExUDNIZ1ZNbV9Saw?oc=5", "title": "Zoetis Cut Its 2026 Guide in Q2 Earnings. The Dermatology Lead Is the Reason.", "content_text": "Zoetis Cut Its 2026 Guide in Q2 Earnings. The Dermatology Lead Is the Reason.", "date_published": "2026-08-09T04:41:29+00:00", "authors": [{"name": "TIKR.com"}], "tags": ["Earnings", "ZOE"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ZOE", "name": "Zoetis Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/9868334b-e8e6-4920-88df-16cb72348fce/"}]}}, {"id": "source:eec75b916e78d13e1aeb0e953ce1b12e808fcc907458f7cf34490e1ddba98873", "url": "https://seekingalpha.com/news/4629325-earnings-scorecard-95-healthcare-firm-deliver-eps-wins-this-week?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4629325-earnings-scorecard-95-healthcare-firm-deliver-eps-wins-this-week?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Earnings Scorecard: 95% of healthcare firms deliver EPS wins this week", "content_text": "Major healthcare heavyweights, including Pfizer (PFE [https://seekingalpha.com/symbol/PFE]), Merck (MRK [https://seekingalpha.com/symbol/MRK]), and Eli Lilly (LLY [https://seekingalpha.com/symbol/LLY]), reported their quarterly earnings this week, pushing the healthcare sector into positive territory after five consecutive sessions of losses. The State Street Health Care Select Sector SPDR ETF [https://seekingalpha.com/symbol/XLV] (XLV [https://seekingalpha.com/symbol/XLV]) rose 1.36% in the week so far. On a YTD basis, XLV has added more than 5%; however, it is lagging behind the broader S&P ", "date_published": "2026-08-08T15:15:33+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Earnings", "ZOE"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ZOE", "name": "Zoetis Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/9868334b-e8e6-4920-88df-16cb72348fce/"}]}}, {"id": "source:65c501c1c638f7531f78e8db7cdf4882b650c5e9b293e183b4d84c68a1ef0849", "url": "https://finance.yahoo.com/healthcare/articles/elanco-animal-health-q2-earnings-060351329.html", "external_url": "https://finance.yahoo.com/healthcare/articles/elanco-animal-health-q2-earnings-060351329.html", "title": "Elanco Animal Health Q2 Earnings Call Highlights", "content_text": "Key Points Interested in Elanco Animal Health Incorporated? Here are five stocks we like better. Strong Q2 performance: Elanco reported revenue of $1.368 billion, up 10% year over year, while adjusted EBITDA rose 21% to $288 million and adjusted EPS increased 31% to $0.34. Pet health drove growth: U.S. and international pet-health revenue increased 11% and 9% organically, respectively, led by Zenrelia and Credelio Quattro. Zenrelia surpassed 2.5 million dogs treated and reached more than 60% of U.S. veterinary clinics. Outlook raised: Elanco lifted its full-year organic constant-currency reven", "date_published": "2026-08-08T06:03:51+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ZOE"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ZOE", "name": "Zoetis Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/9868334b-e8e6-4920-88df-16cb72348fce/"}]}}, {"id": "source:e5d27de15d2732133b352f82dd68537e62857fe9e069243fab551a850b772eab", "url": "https://news.google.com/rss/articles/CBMiY0FVX3lxTFBtaEx3RDhKWEVaZmdqMzNPYXg5Ml82QzBxbGlXbkRZMktrSWVMcUd4YjVhSXRwSmFLd0x0dHo4UldQQ3Q2ZlNvdTRlSXc3NUpCd2szcUdzanJzNTNHUnktUXo4dw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiY0FVX3lxTFBtaEx3RDhKWEVaZmdqMzNPYXg5Ml82QzBxbGlXbkRZMktrSWVMcUd4YjVhSXRwSmFLd0x0dHo4UldQQ3Q2ZlNvdTRlSXc3NUpCd2szcUdzanJzNTNHUnktUXo4dw?oc=5", "title": "Evotec SE (EVO) Aktuelle Aktien-News", "content_text": "Evotec SE (EVO) Aktuelle Aktien-News", "date_published": "2026-08-08T02:32:39+00:00", "authors": [{"name": "TradingKey"}], "tags": ["Market update", "EVT"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "EVT", "name": "Evotec SE", "sentiment_url": "https://sharemaestro.com/sentiment/29b04225-86fc-4492-9acb-4ad0a081d4c2/"}]}}, {"id": "source:52d58b0944e8b22d6d9499ec6fcdb234e01ed441b2163f7252ed58eeb9ddc047", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNNkotVFdIRkp4VlVoUk4yc01XdHktaFpTMEI2WDg5ODc2UGNLQjZMcHFGcXRtaXVFeWRSZ2UyV2oyamZGV2lwaFRmNGlNeTJrR2Rsc3ZWNFY5emFBRkc3ckp4NS15MEp1QXpVLXZ0ZFFyUDFONkhmbFd2SHBmX0RaaW1uREFuRktyOXF1SHFudDBhanBqU2NZbmtmSDRPMG5UOXhCdHZOakRkd2hnQkg4Vg?oc=5", "external_url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNNkotVFdIRkp4VlVoUk4yc01XdHktaFpTMEI2WDg5ODc2UGNLQjZMcHFGcXRtaXVFeWRSZ2UyV2oyamZGV2lwaFRmNGlNeTJrR2Rsc3ZWNFY5emFBRkc3ckp4NS15MEp1QXpVLXZ0ZFFyUDFONkhmbFd2SHBmX0RaaW1uREFuRktyOXF1SHFudDBhanBqU2NZbmtmSDRPMG5UOXhCdHZOakRkd2hnQkg4Vg?oc=5", "title": "Merck KGaA hebt nach starkem Q2 die Prognose f\u00fcr 2026 an", "content_text": "Merck KGaA hebt nach starkem Q2 die Prognose f\u00fcr 2026 an", "date_published": "2026-08-06T14:01:00+00:00", "authors": [{"name": "Investing.com Deutsch"}], "tags": ["Market update", "MRK"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MRK", "name": "Merck KGaA", "sentiment_url": "https://sharemaestro.com/sentiment/d40575c6-c1e0-4c88-afb7-fa233fffc9b7/"}]}}, {"id": "source:8118c2f67dfe134f758541351d31005441763660777ef4bbb0d6828fb4458168", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxPWlJKdERWQkxJRDROdHhyOWg3Nnc1QVRPVkVRUFlMQm1paUdNTUp3VndhbFhmSFRnTm1TZG5FVl9EeDQxalpnOTRocnZaTWEtWGVsOXRMT0RacU1RUGN0bkF0MjNUOWxHcHJwdFNxbHo1QnVjV1BRT3dqbE9fZk5iekxmTTBBU0U1Tm9LbjF3MTFnMzJKMktIR1drUXpPV203WU9SYkJCRnNUOThzN2FuYTlhT2JXZWZrUGNqdG9QMm9pMU0?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxPWlJKdERWQkxJRDROdHhyOWg3Nnc1QVRPVkVRUFlMQm1paUdNTUp3VndhbFhmSFRnTm1TZG5FVl9EeDQxalpnOTRocnZaTWEtWGVsOXRMT0RacU1RUGN0bkF0MjNUOWxHcHJwdFNxbHo1QnVjV1BRT3dqbE9fZk5iekxmTTBBU0U1Tm9LbjF3MTFnMzJKMktIR1drUXpPV203WU9SYkJCRnNUOThzN2FuYTlhT2JXZWZrUGNqdG9QMm9pMU0?oc=5", "title": "Zoetis Inc. passt Gewinnprognose f\u00fcr das Gesamtjahr 2026 an", "content_text": "Zoetis Inc. passt Gewinnprognose f\u00fcr das Gesamtjahr 2026 an", "date_published": "2026-08-06T12:36:46+00:00", "authors": [{"name": "MarketScreener Schweiz"}], "tags": ["Market update", "ZOE"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ZOE", "name": "Zoetis Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/9868334b-e8e6-4920-88df-16cb72348fce/"}]}}, {"id": "source:6cde34f47131fdf5ec6900704a92df3df3900485bbc2a75a1d6cde3b6b617d2e", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQZEMycnJKaEpBZFFLSXVZQTVheUIwZXVIUHBpY0lQVlJ1em5wRl9TTkZMbkRhTjRwczBWUjJfYUxpQVpMeEdvNndzT3F5T3pyZXBNbW1ESnJsdVhURGlpUEJXdnhDWUpDQURrMmdGMnk0cDNxMlBMa3prcy1oVmZkWUpqRG5yVVhHekEtT3cxNnBES2Nxc1RrdjhfcGNBUmpFZVBKUWg0NE5yS0FYYkdWSE83eGx6S3R5c3M0dQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQZEMycnJKaEpBZFFLSXVZQTVheUIwZXVIUHBpY0lQVlJ1em5wRl9TTkZMbkRhTjRwczBWUjJfYUxpQVpMeEdvNndzT3F5T3pyZXBNbW1ESnJsdVhURGlpUEJXdnhDWUpDQURrMmdGMnk0cDNxMlBMa3prcy1oVmZkWUpqRG5yVVhHekEtT3cxNnBES2Nxc1RrdjhfcGNBUmpFZVBKUWg0NE5yS0FYYkdWSE83eGx6S3R5c3M0dQ?oc=5", "title": "Merck KGaA gibt Ergebnisprognose f\u00fcr das Jahr 2026 ab", "content_text": "Merck KGaA gibt Ergebnisprognose f\u00fcr das Jahr 2026 ab", "date_published": "2026-08-06T12:00:00+00:00", "authors": [{"name": "MarketScreener Deutschland"}], "tags": ["Market update", "MRK"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MRK", "name": "Merck KGaA", "sentiment_url": "https://sharemaestro.com/sentiment/d40575c6-c1e0-4c88-afb7-fa233fffc9b7/"}]}}, {"id": "source:70e73acf1124d53c249b2640cd4367d014984c93403b979b62e46d47415d487e", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTE1iWHdaV0NaMTZJTGN3dXZRNER5a1gzVk5reUtUYUF1NFhNalNjTGhDVEZsQ29lZlY1dDVJYU9Pb0lMVUtKQm5pc1plb3lYTWpZTmtfeEl6ZV9IbGh3QXhOemtIVkJCTFRt?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTE1iWHdaV0NaMTZJTGN3dXZRNER5a1gzVk5reUtUYUF1NFhNalNjTGhDVEZsQ29lZlY1dDVJYU9Pb0lMVUtKQm5pc1plb3lYTWpZTmtfeEl6ZV9IbGh3QXhOemtIVkJCTFRt?oc=5", "title": "Evotec SE (EVO) Gewinnprognose: Zuk\u00fcnftige EPS & Umsatzwachstumsprognosen", "content_text": "Evotec SE (EVO) Gewinnprognose: Zuk\u00fcnftige EPS & Umsatzwachstumsprognosen", "date_published": "2026-08-06T07:00:00+00:00", "authors": [{"name": "TradingKey"}], "tags": ["Earnings", "EVT"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "EVT", "name": "Evotec SE", "sentiment_url": "https://sharemaestro.com/sentiment/29b04225-86fc-4492-9acb-4ad0a081d4c2/"}]}}, {"id": "source:577c0ba96b0f1fb043f784de8811a0c2bada956a22b238b64b00549f1e77bbda", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTE9WQTNDcjNSREh2M1A2N2tCTlBVNDAtU0NXUHdMNTNYbTBjM0dpTkhkVUdLclBwd3loQ2tELW81T1ZaZzVIdjc2cmFBNzN1aUYtNkwtX3F1bjk2Z2p5X2pnY2JvcXhnVHJqdFRydXBrcERiNFExQXNQZGtWMzljQQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMifkFVX3lxTE9WQTNDcjNSREh2M1A2N2tCTlBVNDAtU0NXUHdMNTNYbTBjM0dpTkhkVUdLclBwd3loQ2tELW81T1ZaZzVIdjc2cmFBNzN1aUYtNkwtX3F1bjk2Z2p5X2pnY2JvcXhnVHJqdFRydXBrcERiNFExQXNQZGtWMzljQQ?oc=5", "title": "Evotec Aktie kaufen oder verkaufen? Analyse & Prognose 2026", "content_text": "Evotec Aktie kaufen oder verkaufen? Analyse & Prognose 2026", "date_published": "2026-07-30T07:00:00+00:00", "authors": [{"name": "B\u00f6rse Express"}], "tags": ["Market update", "EVT"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "EVT", "name": "Evotec SE", "sentiment_url": "https://sharemaestro.com/sentiment/29b04225-86fc-4492-9acb-4ad0a081d4c2/"}]}}, {"id": "source:b58bc27d92c45d073d5abec9dff75db66e8d70b7ddbf62ae44d07babbacb0f35", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNdnJLSDIzeHpEWWkzM2VjVDBYdjZ3WmcwSzhGclh1VGRYWnU3b0dyd2k0YVJkV1hNTkU0SlBQUWEySnR4eUVuMGR5Q3FlaG9WTzZqZWdLMEFJSjdzTkxFQ0s3QUYzNk90cHEzaGZNX2dJd2R3NlZhNUQ5cmIzcHVWVEpxdjR2Rm9FLUZKWXYtbFNEaHUxRE1maS0tbFRPbjNYWlZR?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNdnJLSDIzeHpEWWkzM2VjVDBYdjZ3WmcwSzhGclh1VGRYWnU3b0dyd2k0YVJkV1hNTkU0SlBQUWEySnR4eUVuMGR5Q3FlaG9WTzZqZWdLMEFJSjdzTkxFQ0s3QUYzNk90cHEzaGZNX2dJd2R3NlZhNUQ5cmIzcHVWVEpxdjR2Rm9FLUZKWXYtbFNEaHUxRE1maS0tbFRPbjNYWlZR?oc=5", "title": "Evotec Aktie: 28 Prozent Wachstum im Kerngesch\u00e4ft", "content_text": "Evotec Aktie: 28 Prozent Wachstum im Kerngesch\u00e4ft", "date_published": "2026-07-27T07:00:00+00:00", "authors": [{"name": "B\u00f6rse Express"}], "tags": ["Market update", "EVT"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "EVT", "name": "Evotec SE", "sentiment_url": "https://sharemaestro.com/sentiment/29b04225-86fc-4492-9acb-4ad0a081d4c2/"}]}}, {"id": "source:1d47f7a67726147cec767304d9caeea52c5538e7586e8dcaf271e5d8a97bdaee", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQOGx0alI5S3c0SXJQRzd2U2tjbGVnM2hJWlJ0aXR5VGFyM3l2X1ZlM3ZLM2hlMjNaYmhLM28wd2ItZ21RVEpPSEFYTTFDX2xGeVRfTkdUMEJidVN4Sm9wWGpwSy0tTUlhOXA3RjFobUNYcDdMTzJqbUlHb0NnTnNnZzdtUWM4U2FLS0JRYzkxa1lBUDZINzYwN0JsTEFEN1l4V3BtQjY4UldUOHY0ckE?oc=5", "external_url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQOGx0alI5S3c0SXJQRzd2U2tjbGVnM2hJWlJ0aXR5VGFyM3l2X1ZlM3ZLM2hlMjNaYmhLM28wd2ItZ21RVEpPSEFYTTFDX2xGeVRfTkdUMEJidVN4Sm9wWGpwSy0tTUlhOXA3RjFobUNYcDdMTzJqbUlHb0NnTnNnZzdtUWM4U2FLS0JRYzkxa1lBUDZINzYwN0JsTEFEN1l4V3BtQjY4UldUOHY0ckE?oc=5", "title": "Evotec Aktie: Umsatz-Prognose auf 570\u2013610 Millionen gesenkt", "content_text": "Evotec Aktie: Umsatz-Prognose auf 570\u2013610 Millionen gesenkt", "date_published": "2026-07-17T07:00:00+00:00", "authors": [{"name": "B\u00f6rse Express"}], "tags": ["Market update", "EVT"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "EVT", "name": "Evotec SE", "sentiment_url": "https://sharemaestro.com/sentiment/29b04225-86fc-4492-9acb-4ad0a081d4c2/"}]}}, {"id": "source:cad0b10d5d6aee926a7f02c51893dc541a21eb415b9ff969274d62158db37fca", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNR2hxdW1wd3VMMmpPQWJORzh0Z2R0dzh6SnZHdTZaYzNZVE9MMTg4QnRjNDgtN01CZFhFZVptWkJRdDRJay1VSEJVb1JfOGVGZGM5bEFkcHZ3N0xiSnlfZFpSRFFBYTQwTy1adFItamNsZm1OZHk0VThmcGI0QU5PS2l1Z0twaHpHTmo4LTUtUm1sWUhaV1R3ZmJZdTVKRm5HcURN?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNR2hxdW1wd3VMMmpPQWJORzh0Z2R0dzh6SnZHdTZaYzNZVE9MMTg4QnRjNDgtN01CZFhFZVptWkJRdDRJay1VSEJVb1JfOGVGZGM5bEFkcHZ3N0xiSnlfZFpSRFFBYTQwTy1adFItamNsZm1OZHk0VThmcGI0QU5PS2l1Z0twaHpHTmo4LTUtUm1sWUhaV1R3ZmJZdTVKRm5HcURN?oc=5", "title": "Merck KGaA verzeichnet ein solides erstes Quartal", "content_text": "Merck KGaA verzeichnet ein solides erstes Quartal", "date_published": "2026-05-13T07:00:00+00:00", "authors": [{"name": "finanzen.net"}], "tags": ["Market update", "MRK"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MRK", "name": "Merck KGaA", "sentiment_url": "https://sharemaestro.com/sentiment/d40575c6-c1e0-4c88-afb7-fa233fffc9b7/"}]}}, {"id": "source:daeff47b8aef144f0ae81b680bcee08a7ed8a5809d6c9e3d0a7a07909b7fd202", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPRFp0aTU0R2xLeGxVN1JXT1FJa1gyc0dabEZDdy1MS0lFLXNWQUlUbHJKR2xPQ2o0UVZrZml2d0ZPSDNjSkV6SExvbzJCc1V4TVROcFk0dENzTXB6dXVQbnk4dm9qUWY4RDdoMGRLYXU0YV9ieVRwRWhSYXZmTnFVUDhycTJCVnVUbW9KOHp2cUJycUt5d0Ryc0RfSlVydDJvdWJpX2U2MTZEVXpMdDNJNld1cjNHelJsdi1WNmh6aUtZNVps?oc=5", "external_url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPRFp0aTU0R2xLeGxVN1JXT1FJa1gyc0dabEZDdy1MS0lFLXNWQUlUbHJKR2xPQ2o0UVZrZml2d0ZPSDNjSkV6SExvbzJCc1V4TVROcFk0dENzTXB6dXVQbnk4dm9qUWY4RDdoMGRLYXU0YV9ieVRwRWhSYXZmTnFVUDhycTJCVnVUbW9KOHp2cUJycUt5d0Ryc0RfSlVydDJvdWJpX2U2MTZEVXpMdDNJNld1cjNHelJsdi1WNmh6aUtZNVps?oc=5", "title": "Viatris-Aktie f\u00e4llt um 3 %: Schwache Prognose \u00fcberschattet Gewinn\u00fcberraschung", "content_text": "Viatris-Aktie f\u00e4llt um 3 %: Schwache Prognose \u00fcberschattet Gewinn\u00fcberraschung", "date_published": "2026-05-07T07:00:00+00:00", "authors": [{"name": "Investing.com Deutsch"}], "tags": ["Market update", "VIA"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VIA", "name": "Viatris Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/e92f8bbe-0245-4de1-a36d-1a4306c6b65e/"}]}}, {"id": "source:92a8416a83c5eb298283c29aa9a000ae51893887345c987ac928ff75c3459572", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNQUZrMmF0M0d6SF9BdlpZRERUbVdVeEJtWWdOLWx4RFFISTg5cnZITnBDVUJ2b21mcUxIdnJOVDc0NTQ5c1VBVFAyQkhIMHZtTU5JRVJmRTBwMmtDV3ozSi1jTkRfMWhRN19uc2JSWkZKWnQwTWc3Ry1ZNEtEY0FUV1pUcmZabmJIcXhyRUFiekNXQkdTNWpObWlrQ0c1Z2l2NjJoRmF2cmlRM3lPQ1hVQUE5Qm1tZXVVazdr?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNQUZrMmF0M0d6SF9BdlpZRERUbVdVeEJtWWdOLWx4RFFISTg5cnZITnBDVUJ2b21mcUxIdnJOVDc0NTQ5c1VBVFAyQkhIMHZtTU5JRVJmRTBwMmtDV3ozSi1jTkRfMWhRN19uc2JSWkZKWnQwTWc3Ry1ZNEtEY0FUV1pUcmZabmJIcXhyRUFiekNXQkdTNWpObWlrQ0c1Z2l2NjJoRmF2cmlRM3lPQ1hVQUE5Qm1tZXVVazdr?oc=5", "title": "Viatris \u00fcbertrifft Q1-Erwartungen, best\u00e4tigt FY26-Prognose: CFO-Wechse", "content_text": "Viatris \u00fcbertrifft Q1-Erwartungen, best\u00e4tigt FY26-Prognose: CFO-Wechse", "date_published": "2026-05-07T07:00:00+00:00", "authors": [{"name": "Goldesel.de"}], "tags": ["Market update", "VIA"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VIA", "name": "Viatris Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/e92f8bbe-0245-4de1-a36d-1a4306c6b65e/"}]}}, {"id": "source:a8935655cc28b6f2b5ea107747792674bc73c6b03db76bdd9075edc3685d7a1c", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPcC0tLWl3VzVhV1FPMWd6WVFEb0JsaG52bEgtSWFxbVREU3JlTWI5aE9IbTBYc3ZRcU1yN0VfWEw0OXEyS05RZTJoQVpaNXpaNWxXMFhhX1hQRVFNUHBzbHVkaDdmd1dYN2RNZUJzOWxORjRoN0h4RGg5eG9JS3l1TlU0VVR5empCTnoyT1M5QQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPcC0tLWl3VzVhV1FPMWd6WVFEb0JsaG52bEgtSWFxbVREU3JlTWI5aE9IbTBYc3ZRcU1yN0VfWEw0OXEyS05RZTJoQVpaNXpaNWxXMFhhX1hQRVFNUHBzbHVkaDdmd1dYN2RNZUJzOWxORjRoN0h4RGg5eG9JS3l1TlU0VVR5empCTnoyT1M5QQ?oc=5", "title": "Evotec Aktie: Umbau trifft Prognose", "content_text": "Evotec Aktie: Umbau trifft Prognose", "date_published": "2026-04-11T07:00:00+00:00", "authors": [{"name": "B\u00f6rse Express"}], "tags": ["Market update", "EVT"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "EVT", "name": "Evotec SE", "sentiment_url": "https://sharemaestro.com/sentiment/29b04225-86fc-4492-9acb-4ad0a081d4c2/"}]}}, {"id": "source:98f63591d62b58d7148d971fa6ba3f2df8ee36b623255ebe94a8f8b9a41e6f68", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.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?oc=5", "title": "Werden ein flacher Ausblick f\u00fcr 2026 und eine konstante Dividende das Investment-Narrativ von Merck KGaA (XTRA:MRK) ver\u00e4ndern?", "content_text": "Werden ein flacher Ausblick f\u00fcr 2026 und eine konstante Dividende das Investment-Narrativ von Merck KGaA (XTRA:MRK) ver\u00e4ndern?", "date_published": "2026-03-18T07:00:00+00:00", "authors": [{"name": "simplywall.st"}], "tags": ["Market update", "MRK"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MRK", "name": "Merck KGaA", "sentiment_url": "https://sharemaestro.com/sentiment/d40575c6-c1e0-4c88-afb7-fa233fffc9b7/"}]}}, {"id": "source:f24a3e17f8d411736c53d890bce5657e3250e991d802836e7672304cbaebc7a1", "url": "https://news.google.com/rss/articles/CBMi_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?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi_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?oc=5", "title": "EQS-News: Evotec gibt \u201aHorizon\u2018 bekannt \u2013 Meilenstein der strategischen Transformation f\u00fcr schnelleres Wachstum und mehr Agilit\u00e4t - boerse.de", "content_text": "EQS-News: Evotec gibt \u201aHorizon\u2018 bekannt \u2013 Meilenstein der strategischen Transformation f\u00fcr schnelleres Wachstum und mehr Agilit\u00e4t - boerse.de", "date_published": "2026-03-10T07:00:00+00:00", "authors": [{"name": "boerse.de"}], "tags": ["Market update", "EVT"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "EVT", "name": "Evotec SE", "sentiment_url": "https://sharemaestro.com/sentiment/29b04225-86fc-4492-9acb-4ad0a081d4c2/"}]}}, {"id": "source:75bbe115edc72c9909894dbddb0e11a6a32c4576c9a352fa83b9b0300b11d04b", "url": "https://news.google.com/rss/articles/CBMic0FVX3lxTE9WdFFJczBlR0daUzIxblY2bEdjTkVPNDdPNzljUlRIRklyVUExaUxmWkpMNTcwNGFlZkxxTk1iaXJmRjZScDN3TGF6bGtKX013dUE3N25fcC13aHNrdklfM245RS13TGI1bWhWUnU4NjhoNXM?oc=5", "external_url": "https://news.google.com/rss/articles/CBMic0FVX3lxTE9WdFFJczBlR0daUzIxblY2bEdjTkVPNDdPNzljUlRIRklyVUExaUxmWkpMNTcwNGFlZkxxTk1iaXJmRjZScDN3TGF6bGtKX013dUE3N25fcC13aHNrdklfM245RS13TGI1bWhWUnU4NjhoNXM?oc=5", "title": "BioNxt Solutions Inc. Aktie \u2022 A3D1K3 \u2022 CA0909741062", "content_text": "BioNxt Solutions Inc. Aktie \u2022 A3D1K3 \u2022 CA0909741062", "date_published": "2025-05-08T18:08:18+00:00", "authors": [{"name": "Onvista"}], "tags": ["Market update", "BXT"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BXT", "name": "BioNxt Solutions Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/9f3ab08c-8865-432e-abf0-31732de30be7/"}]}}, {"id": "source:04bf88f7384a30bb75fde88979a4389d4a415b8f09e70888411e7d66b52a8c15", "url": "https://news.google.com/rss/articles/CBMidkFVX3lxTE5DRkJjWkwxd3BXeDZnUWhOcEVndHMwbTB6czdsQ2RJelJjTEs4QjRJTFNtQ1Z6Vmw5Z1RkbFg0am1lN0F1TlZvN2t6VVRIN3pYa1ZHRWJjcW9HbUJVZWdoRWtrSHNMc0NScHNXZUhsUU9ac3VIZUE?oc=5", "external_url": "https://news.google.com/rss/articles/CBMidkFVX3lxTE5DRkJjWkwxd3BXeDZnUWhOcEVndHMwbTB6czdsQ2RJelJjTEs4QjRJTFNtQ1Z6Vmw5Z1RkbFg0am1lN0F1TlZvN2t6VVRIN3pYa1ZHRWJjcW9HbUJVZWdoRWtrSHNMc0NScHNXZUhsUU9ac3VIZUE?oc=5", "title": "Evotec SE: Finanzdaten Prognosen Sch\u00e4tzungen und Erwartungen | 566480 | DE0005664809", "content_text": "Evotec SE: Finanzdaten Prognosen Sch\u00e4tzungen und Erwartungen | 566480 | DE0005664809", "date_published": "2024-07-23T11:05:56+00:00", "authors": [{"name": "MarketScreener Deutschland"}], "tags": ["Market update", "EVT"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "EVT", "name": "Evotec SE", "sentiment_url": "https://sharemaestro.com/sentiment/29b04225-86fc-4492-9acb-4ad0a081d4c2/"}]}}, {"id": "source:75bea45ffa1096b8efa84e0b5135609960cacb5683eb28fd7b7c95727bfe0d33", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPWkUwSGFBLU9aWFBZM2V3Z09rdTUzYWo0bTNIZlRKSjc5TlFGcU9nX3VtU3ZvZERISE4tTUVibWNIT1VNa0tEdHJFRmE2TFdsYi1aYTBoUjFubU5UNk9pRmNQWUZ6ejBDZWxvNEJYVzdYM3pHTGJzNkRGMkJ1UTNORXVnN3I5Zw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPWkUwSGFBLU9aWFBZM2V3Z09rdTUzYWo0bTNIZlRKSjc5TlFGcU9nX3VtU3ZvZERISE4tTUVibWNIT1VNa0tEdHJFRmE2TFdsYi1aYTBoUjFubU5UNk9pRmNQWUZ6ejBDZWxvNEJYVzdYM3pHTGJzNkRGMkJ1UTNORXVnN3I5Zw?oc=5", "title": "Evotec SE: Konsensus der Analysten und Kursziel | 566480 | DE0005664809", "content_text": "Evotec SE: Konsensus der Analysten und Kursziel | 566480 | DE0005664809", "date_published": "2020-08-18T20:29:20+00:00", "authors": [{"name": "MarketScreener Deutschland"}], "tags": ["Market update", "EVT"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "EVT", "name": "Evotec SE", "sentiment_url": "https://sharemaestro.com/sentiment/29b04225-86fc-4492-9acb-4ad0a081d4c2/"}]}}, {"id": "source:11795983e215b496a10ec8646d28325b74a3fd0f05c91825d8630df3a70b49b3", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPSXN3NVFKd09MSWx0QU1GYm0zYjJMODhLaHJLNEo4UmxVeTZaaTZMeFJsOEJaQm16ZERGVjA5WXFhMkFOekpMaThINDlxWVozU1Mwb1V6bDJDaGtfYVN1aWw3SUlYN1pZc0NzUXR6NkN2MS01a1h6czExNFIwajJtUFlnSHItb1NqLXNxSHdyVGtkQkxXbG9ZbA?oc=5", "external_url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPSXN3NVFKd09MSWx0QU1GYm0zYjJMODhLaHJLNEo4UmxVeTZaaTZMeFJsOEJaQm16ZERGVjA5WXFhMkFOekpMaThINDlxWVozU1Mwb1V6bDJDaGtfYVN1aWw3SUlYN1pZc0NzUXR6NkN2MS01a1h6czExNFIwajJtUFlnSHItb1NqLXNxSHdyVGtkQkxXbG9ZbA?oc=5", "title": "Dermapharm Holding SE: Konsensus der Analysten und Kursziel | A2GS5D | DE000A2GS5D8", "content_text": "Dermapharm Holding SE: Konsensus der Analysten und Kursziel | A2GS5D | DE000A2GS5D8", "date_published": "2020-08-18T18:48:33+00:00", "authors": [{"name": "MarketScreener Deutschland"}], "tags": ["Market update", "DMP"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "DMP", "name": "Dermapharm Holding SE", "sentiment_url": "https://sharemaestro.com/sentiment/69aa276b-d53f-4877-82f6-2d5c0a5602d6/"}]}}]}